HomeCompareAFMD vs SPHD

AFMD vs SPHD: Dividend Comparison 2026

AFMD yields 1101.93% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AFMD wins by $44144481.98M in total portfolio value
10 years
AFMD
AFMD
● Live price
1101.93%
Share price
$0.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44144482.00M
Annual income
$37,457,590,875,373.99
Full AFMD calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — AFMD vs SPHD

📍 AFMD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAFMDSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AFMD + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AFMD pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AFMD
Annual income on $10K today (after 15% tax)
$93,663.91/yr
After 10yr DRIP, annual income (after tax)
$31,838,952,244,067.89/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, AFMD beats the other by $31,838,952,243,582.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AFMD + SPHD for your $10,000?

AFMD: 50%SPHD: 50%
100% SPHD50/50100% AFMD
Portfolio after 10yr
$22072241.02M
Annual income
$18,728,795,437,972.66/yr
Blended yield
84.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AFMD right now

AFMD
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$7.50
+4032.2% upside vs current
Range: $5.00 — $10.00
Altman Z
-25.6
Piotroski
1/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AFMD buys
0
SPHD buys
0
No recent congressional trades found for AFMD or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAFMDSPHD
Forward yield1101.93%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$44144482.00M$26.5K
Annual income after 10y$37,457,590,875,373.99$571.32
Total dividends collected$43640208.51M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: AFMD vs SPHD ($10,000, DRIP)

YearAFMD PortfolioAFMD Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$120,893$110,192.84$11,133$432.85+$109.8KAFMD
2$1,374,358$1,245,002.32$12,363$450.36+$1.36MAFMD
3$14,698,300$13,227,737.75$13,695$467.39+$14.68MAFMD
4$147,938,657$132,211,475.91$15,138$483.90+$147.92MAFMD
5$1,401,949,387$1,243,655,023.61$16,697$499.88+$1401.93MAFMD
6$12,514,637,219$11,014,551,374.87$18,382$515.31+$12514.62MAFMD
7$105,280,812,731$91,890,150,906.24$20,198$530.17+$105280.79MAFMD
8$835,114,369,934$722,463,900,312.29$22,157$544.46+$835114.35MAFMD
9$6,249,430,961,556$5,355,858,585,726.27$24,266$558.18+$6249430.94MAFMD
10$44,144,482,004,238$37,457,590,875,373.99$26,536$571.32+$44144481.98MAFMD

AFMD vs SPHD: Complete Analysis 2026

AFMDStock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Full AFMD Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this AFMD vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AFMD vs SCHDAFMD vs JEPIAFMD vs OAFMD vs KOAFMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.